PT  - JOURNAL ARTICLE
AU  - Bykerk, Vivian P.
AU  - Lie, Elisabeth
AU  - Bartlett, Susan J.
AU  - Alten, Rieke
AU  - Boonen, Annelies
AU  - Christensen, Robin
AU  - Furst, Daniel E.
AU  - Hewlett, Sarah
AU  - Leong, Amye L.
AU  - Lyddiatt, Anne
AU  - March, Lyn
AU  - May, James E.
AU  - Montie, Pam
AU  - Orbai, Ana-Maria
AU  - Pohl, Christoph
AU  - Scholte Voshaar, Marieke
AU  - Woodworth, Thasia
AU  - Bingham, Clifton O.
AU  - Choy, Ernest H.
TI  - Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop
AID  - 10.3899/jrheum.131252
DP  - 2014 Apr 01
TA  - The Journal of Rheumatology
PG  - 799--809
VI  - 41
IP  - 4
4099  - http://www.jrheum.org/content/41/4/799.short
4100  - http://www.jrheum.org/content/41/4/799.full
SO  - J Rheumatol2014 Apr 01; 41
AB  - Objective. The OMERACT Rheumatoid Arthritis (RA) Flare Group (FG) is developing a data-driven, patient-inclusive, consensus-based RA flare definition for use in clinical trials, longterm observational studies, and clinical practice. At OMERACT 11, we sought endorsement of a proposed core domain set to measure RA flare. Methods. Patient and healthcare professional (HCP) qualitative studies, focus groups, and literature review, followed by patient and HCP Delphi exercises including combined Delphi consensus at Outcome Measures in Rheumatology 10 (OMERACT 10), identified potential domains to measure flare. At OMERACT 11, breakout groups discussed key domains and instruments to measure them, and proposed a research agenda. Patients were active research partners in all focus groups and domain identification activities. Processes for domain selection and patient partner involvement were case studies for OMERACT Filter 2.0 methodology. Results. A pre-meeting combined Delphi exercise for defining flare identified 9 domains as important (> 70% consensus from patients or HCP). Four new patient-reported domains beyond those included in the RA disease activity core set were proposed for inclusion (fatigue, participation, stiffness, and self-management). The RA FG developed preliminary flare questions (PFQ) to measure domains. In combined plenary voting sessions, OMERACT 11 attendees endorsed the proposed RA core set to measure flare with ≥ 78% consensus and the addition of 3 additional domains to the research agenda for OMERACT 12. Conclusion. At OMERACT 11, a core domain set to measure RA flare was ratified and endorsed by attendees. Domain validation aligning with Filter 2.0 is ongoing in new randomized controlled clinical trials and longitudinal observational studies using existing and new instruments including a set of PFQ.